Harbin Pharmaceutical Group Co., Ltd.
Harbin Pharmaceutical Group Co., Ltd., commonly referred to as Harbin Pharma, is a leading player in the pharmaceutical preparation manufacturing industry, headquartered in Harbin, China. Established in 1994, the company has made significant strides in the development and production of a diverse range of pharmaceutical products, including traditional Chinese medicines and modern pharmaceuticals.
With a strong presence in both domestic and international markets, Harbin Pharma is renowned for its commitment to quality and innovation. The company’s core offerings include injectable drugs, tablets, and herbal medicines, distinguished by their efficacy and adherence to stringent safety standards. Over the years, Harbin Pharmaceutical Group has achieved notable milestones, solidifying its position as a trusted name in the healthcare sector, and continues to expand its operational footprint across various regions.
-15 vs industry average
Harbin Pharmaceutical Group Co., Ltd.’s score of 25 is lower than 40% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Harbin Pharmaceutical Group Co., Ltd.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing is among the most carbon-intensive industries
Industry performance
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Reported emissions
No reported emissions data is available for Harbin Pharmaceutical Group Co., Ltd. yet.
Harbin Pharmaceutical Group Co., Ltd.'s reported carbon emissions
As of the latest available information, Harbin Pharmaceutical Group Co., Ltd., based in China and operating within the Pharmaceutical Preparation Manufacturing industry, has not publicly disclosed specific absolute carbon emissions data in kg CO2e.
However, the company has established climate commitments. It aims to reduce absolute Scope 1 and 2 greenhouse gas emissions by 82% by 2030, using 2019 as a base year. Additionally, Harbin Pharmaceutical Group Co., Ltd. is committed to reducing absolute Scope 3 greenhouse gas emissions by 14% by 2030, also from a 2019 baseline. These Scope 3 reductions specifically target categories including purchased goods and services, upstream transportation and distribution, waste generated in operations, and downstream transportation and distribution.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Harbin Pharmaceutical Group Co., Ltd.’s Climate Goals (2030 & 2050)
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Harbin Pharmaceutical Group Co., Ltd.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project